Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX)
| CAPS Rating |
|
|---|
SOMX
VS S&P 500 (SPY)
SOMX News and Commentary
- Somaxon Says P&G Passed On Negotiation Over OTC Insomnia Drug – SmartMoney
- Avoid This Drug Stock – The Motley Fool
- Avoid This Biotech Stock – The Motley Fool
- Stocks Off Lows as Fed Paints Bleak Jobs Picture; Factory Orders Top Street – NASDAQ
- Mid-Day Update: Stocks Mixed as Fed Paints Dim Jobs Picture; Greece Default Worries Linger – NASDAQ
- 3 Stocks Shaking the Market – The Motley Fool
- Somaxon's Bore of a Quarter – The Motley Fool
- Somaxon Discloses Patent-Infringement Suit Against Mylan – SmartMoney
- 3 Ways to Play Biotech With Options – The Motley Fool
This ticker is not currently Ratable.
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
142
Outperform
16
Underperform
All-Star Players
25
Outperform
4
Underperform
Wall Street
3
Outperform
0
Underperform
RSS Headlines
Fool UK
